ClinicalTrials.gg
Active, not recruitingNCT07223697Velarite-LTEUpdated Oct 26, 2026

A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis

A Phase 2 interventional study of Afimkibart in Atopic Dermatitis, sponsored by Hoffmann-La Roche. Active, not recruiting at 31 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Updated Oct 26, 2026Now Active, not recruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies in Dermatitis, Atopic with a site in Brazil — 2 open to participants now, 12 under way, 6 of them phase 3. Dermatitis, Atopic · Brazil.

Planned enrollment
24th of 35
120 · median 310
Started
2026
with 2 others
Phase 2
5 of 38
none open now
Primary completion
2033-03
later than 10 of 11 live
Registered
35th of 38
by date
Lead sponsor
2 of 38
Hoffmann-La Roche

Among the 38 studies in Dermatitis, Atopic with a site in Brazil, this one is the 24th largest by planned enrollment of the 35 interventional ones that give a count, is one of 3 that started in 2026, is one of 5 in phase 2, reaches primary completion later than 10 of the 11 other live ones, and was the 35th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

2 of the 38 studies in Dermatitis, Atopic with a site in Brazil are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Dermatitis, Atopic with a site in Brazil, or all of them as a file.
02

Study summary

This study will assess long-term safety and efficacy of Afimkibart (also known as RO7790121) in participants with Atopic Dermatitis (AD) who participated in previous afimkibart clinical trials.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability and willingness to comply with all aspects of the protocol including completion of the efficacy assessments (EASI and IGA), clinical outcome assessment instruments (DLQI, POEM), and safety and PK sample collections for the duration of the study

Parent Clinical Trial-Specific Criteria:

  • Study CS45570 participants who continued to be evaluated at the Week 36 follow up visit and achieved => EASI50 response from study baseline

Exclusion criteria

Exclusion Criteria:

  • Evidence of other skin conditions that would interfere with the assessment of AD
  • Withdrawal of consent and/or premature discontinuation from parent study
  • Any permanent discontinuation of study drug in parent study
  • History of severe allergic reaction or anaphylactic reaction to any biologic agent or known to any component of Afimkibart
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Afimkibart Group I

    Participants will receive Afimkibart as subcutaneous (SC) injection.

    Drug: Afimkibart

  • Experimental
    Afimkibart Group II

    Participants will receive Afimkibart as SC injection.

    Drug: Afimkibart

Interventions

  • Afimkibart SC injection will be administered as per the schedule defined in the protocol.

    Also known as: RO7790121, PF-06480605, RVT-3101

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with Adverse Events

    Time frame: From Baseline up to 6 years

Secondary outcomes

  1. Change From Baseline (in Parent Study) in Eczema Area and Severity Index (EASI) Score at Each Visit

    Time frame: Baseline, Up to 6 years

  2. Percent Change From Baseline (in Parent Study) in EASI Score at Each Visit

    Time frame: Baseline, Up to 6 years

  3. Percentage of Participants With EASI-50 at Each Visit

    Time frame: Up to 6 years

  4. Percentage of Participants with EASI-75 at Each Visit

    Time frame: Up to 6 years

  5. Percentage of Participants with EASI-90 at Each Visit

    Time frame: Up to 6 years

  6. Percentage of Participants who Achieve Validated Investigator Global Assessment Scale for Atopic Dermatitis (vIGA-AD) of Clear (0) or Almost clear (1) at Each Visit

    Time frame: From Baseline up to 6 years

  7. Change from Baseline (in the parent study) in Participant-Oriented Eczema Measure (POEM) at Each Visit

    Time frame: Baseline, Up to 6 years

  8. Change from Baseline (in the parent study) in Dermatology Life Quality Index (DLQI) at Each Visit

    Time frame: Baseline, Up to 6 years

  9. Serum Concentration of Afimkibart at Specified Timepoints

    Time frame: Pre-dose on Day 1, Weeks 2, 10, 18, 26, 34, 42, 50 74, 98, 122, 146, 170, 194, 218, 242, 266, 290 and 14 weeks after last dose

  10. Percentage of Participants with Anti-Drug Antibodies (ADAs) to Afimkibart

    Time frame: From Baseline up to 6 years

  11. Percentage of Participants with Neutralizing Antibody (NAb) to Afimkibart

    Time frame: From Baseline up to 6 years

07

Study locations

31 sites
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Mar 2033, 85 months after the start.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's planned 85 months is above that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2025
First posted
Nov 3, 2025
StartActual
Jan 8, 2026
Primary completionEst.
Mar 1, 2033
CompletionEst.
Mar 1, 2033
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 26, 2026
Sites
4 sites added, 2 sites removed. 25 sites changed recruiting status (25 now active, not recruiting)
Show 25 sites
  • UCLA Division of Dermatology · Los Angeles, United StatesRecruiting→Active, not recruiting
  • Dermatology Research Associate · Los Angeles, United StatesRecruiting→Active, not recruiting
  • Olympian Clinical Research · Tampa, United StatesRecruiting→Active, not recruiting
  • Hamilton Research, LLC · Alpharetta, United StatesRecruiting→Active, not recruiting
  • Revival Research Institute, LLC · Troy, United StatesRecruiting→Active, not recruiting
  • Best Skin Research LLC · Camp Hill, United StatesRecruiting→Active, not recruiting
  • Irmandade Da Santa Casa de Misericordia de Porto Alegre · Porto Alegre, BrazilRecruiting→Active, not recruiting
  • Hospital de Clnicas de Porto Alegre · Porto Alegre, BrazilRecruiting→Active, not recruiting
  • UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu · Botucatu, BrazilRecruiting→Active, not recruiting
  • Centro de Pesquisa São Lucas · Campinas, BrazilRecruiting→Active, not recruiting
  • Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto Hospital de Base - PPDS · Sao Jose Rio Preto, BrazilRecruiting→Active, not recruiting
  • Instituto Brasil de Pesquisa Clínica-IBPCLIN S/A · Rio de Janeiro, BrazilRecruiting→Active, not recruiting
  • DermEffects · London, CanadaRecruiting→Active, not recruiting
  • Lynderm Research Inc · Markham, CanadaRecruiting→Active, not recruiting
  • Ryan Clinical Research Inc · Newmarket, CanadaRecruiting→Active, not recruiting
  • Fachklinik Bad Bentheim · Bad Bentheim, GermanyRecruiting→Active, not recruiting
  • Dermatologikum Hamburg Gemeinschaftspraxis GbR · Hamburg, GermanyRecruiting→Active, not recruiting
  • Azienda Ospedaliero Universitaria delle Marche · Ancona, ItalyRecruiting→Active, not recruiting
  • Centrum Medyczne Pratia Katowice I · Katowice, PolandRecruiting→Active, not recruiting
  • Centrum Medyczne Pratia Gdynia · Gdynia, PolandRecruiting→Active, not recruiting
  • Centrum Nowoczesnych Terapii "Dobry Lekarz" · Krakow, PolandRecruiting→Active, not recruiting
  • Uniwersytecki Szpital Kliniczny im.Fryderyka Chopina w Rzeszowie · Rzeszów, PolandRecruiting→Active, not recruiting
  • Klinika Ambroziak Dermatologia · Warsaw, PolandRecruiting→Active, not recruiting
  • Clinica Universidad de Navarra · Pamplona, SpainRecruiting→Active, not recruiting
  • Hospital Universitario Reina Sofia · Córdoba, SpainRecruiting→Active, not recruiting
Show 4 added (1 United States, 1 Canada, 1 Italy, 1 Poland)
  • University of Minnesota · Minneapolis, United States
  • DermEdge Research · Mississauga, Canada
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Rome, Italy
  • Specjalistyczny Gabinet Dermatologiczny Aplikacyjno-Badawczy Marek Brzewski, Pawel Brzewski s.c. · Krakow, Poland
Show 2 removed
  • DermEdge · Mississauga, Canada
  • Specjalistyczny Gabinet Dermatologiczny dr n. med. Pawel Brzewski · Krakow, Poland
Oct 6, 2026
Show all 2 updates
  1. Oct 26, 2026
    Recruiting→Active, not recruiting
    + 2 other changes: contact details and site details
  2. Oct 6, 2026
    4 sites added, 2 sites removed. 25 sites changed recruiting status (25 now active, not recruiting)
    Show 25 sites
    • UCLA Division of Dermatology · Los Angeles, United StatesRecruiting→Active, not recruiting
    • Dermatology Research Associate · Los Angeles, United StatesRecruiting→Active, not recruiting
    • Olympian Clinical Research · Tampa, United StatesRecruiting→Active, not recruiting
    • Hamilton Research, LLC · Alpharetta, United StatesRecruiting→Active, not recruiting
    • Revival Research Institute, LLC · Troy, United StatesRecruiting→Active, not recruiting
    • Best Skin Research LLC · Camp Hill, United StatesRecruiting→Active, not recruiting
    • Irmandade Da Santa Casa de Misericordia de Porto Alegre · Porto Alegre, BrazilRecruiting→Active, not recruiting
    • Hospital de Clnicas de Porto Alegre · Porto Alegre, BrazilRecruiting→Active, not recruiting
    • UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu · Botucatu, BrazilRecruiting→Active, not recruiting
    • Centro de Pesquisa São Lucas · Campinas, BrazilRecruiting→Active, not recruiting
    • Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto Hospital de Base - PPDS · Sao Jose Rio Preto, BrazilRecruiting→Active, not recruiting
    • Instituto Brasil de Pesquisa Clínica-IBPCLIN S/A · Rio de Janeiro, BrazilRecruiting→Active, not recruiting
    • DermEffects · London, CanadaRecruiting→Active, not recruiting
    • Lynderm Research Inc · Markham, CanadaRecruiting→Active, not recruiting
    • Ryan Clinical Research Inc · Newmarket, CanadaRecruiting→Active, not recruiting
    • Fachklinik Bad Bentheim · Bad Bentheim, GermanyRecruiting→Active, not recruiting
    • Dermatologikum Hamburg Gemeinschaftspraxis GbR · Hamburg, GermanyRecruiting→Active, not recruiting
    • Azienda Ospedaliero Universitaria delle Marche · Ancona, ItalyRecruiting→Active, not recruiting
    • Centrum Medyczne Pratia Katowice I · Katowice, PolandRecruiting→Active, not recruiting
    • Centrum Medyczne Pratia Gdynia · Gdynia, PolandRecruiting→Active, not recruiting
    • Centrum Nowoczesnych Terapii "Dobry Lekarz" · Krakow, PolandRecruiting→Active, not recruiting
    • Uniwersytecki Szpital Kliniczny im.Fryderyka Chopina w Rzeszowie · Rzeszów, PolandRecruiting→Active, not recruiting
    • Klinika Ambroziak Dermatologia · Warsaw, PolandRecruiting→Active, not recruiting
    • Clinica Universidad de Navarra · Pamplona, SpainRecruiting→Active, not recruiting
    • Hospital Universitario Reina Sofia · Córdoba, SpainRecruiting→Active, not recruiting
    Show 4 added (1 United States, 1 Canada, 1 Italy, 1 Poland)
    • University of Minnesota · Minneapolis, United States
    • DermEdge Research · Mississauga, Canada
    • Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Rome, Italy
    • Specjalistyczny Gabinet Dermatologiczny Aplikacyjno-Badawczy Marek Brzewski, Pawel Brzewski s.c. · Krakow, Poland
    Show 2 removed
    • DermEdge · Mississauga, Canada
    • Specjalistyczny Gabinet Dermatologiczny dr n. med. Pawel Brzewski · Krakow, Poland
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07223697
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Nov 3, 2025
Start date
Jan 8, 2026
Primary completion
Mar 1, 2033 (estimated)
Completion
Mar 1, 2033 (estimated)
Last update
Oct 26, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Afimkibart

Start the discussion